Concomitant phenytoin therapy doubles the osteogenic and densitometric effect of fluoride therapy in osteoporosis

J. R. Talbot(Universidad del Salvador), D J Baylink(Instituto de Diagnóstico e Investigaciones Metabólicas), José Zanchetta(Universidad del Salvador), J. Gonzalez-Paredes(Instituto de Diagnóstico e Investigaciones Metabólicas), Horacio Plotkin(Instituto de Diagnóstico e Investigaciones Metabólicas)
Osteoporosis International
January 1, 1996
10.1007/bf02500557
Cited by 0

Related Papers

Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
|Journal of Bone and Mineral Research|2008|508
Effects of teriparatide versus alendronate for treating glucocorticoid‐induced osteoporosis: Thirty‐six–month results of a randomized, double‐blind, controlled trial
|Arthritis & Rheumatism|2009|497